Published in Eur Heart J on February 04, 2009
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (2011) 2.68
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol (2012) 1.44
Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J (2015) 1.29
CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet (2011) 1.05
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J (2011) 0.94
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther (2013) 0.91
Genetics of platelet inhibitor treatment. Br J Clin Pharmacol (2014) 0.89
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol (2011) 0.87
Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med (2010) 0.87
Recent advances in the diagnosis and treatment of acute myocardial infarction. World J Cardiol (2015) 0.85
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej (2015) 0.84
The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol (2011) 0.84
A surveillance tool to support quality assurance and research in personalized medicine. AMIA Annu Symp Proc (2011) 0.84
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian Heart J (2012) 0.83
Recent advances in the pharmacogenetics of clopidogrel. Hum Genet (2011) 0.83
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet (2013) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmgenomics Pers Med (2013) 0.83
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS One (2014) 0.82
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation (2015) 0.81
Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther (2011) 0.81
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thromb J (2011) 0.81
Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep (2013) 0.81
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia. Sci Rep (2016) 0.80
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol (2015) 0.79
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med (2015) 0.79
Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. Br J Clin Pharmacol (2011) 0.79
Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet Genomics (2016) 0.79
CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One (2013) 0.78
Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population. PLoS One (2012) 0.78
Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. Eur J Clin Pharmacol (2012) 0.77
Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet (2015) 0.77
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups. PLoS One (2013) 0.77
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. Crit Pathw Cardiol (2010) 0.76
Genetic determinations of variable responsiveness to clopidogrel and implications for neurointerventional procedures. Interv Neurol (2012) 0.76
Platelet Function Testing-Guided Antiplatelet Therapy. EJIFCC (2013) 0.75
Personalized healthcare in clotting disorders. Per Med (2010) 0.75
Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese. J Res Med Sci (2016) 0.75
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? Curr Opin Cardiol (2013) 0.75
The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs. Dis Markers (2015) 0.75
Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients. Exp Ther Med (2015) 0.75
CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. Saudi Pharm J (2016) 0.75
Clopidogrel resistance - a clear problem with an unclear solution. Indian Heart J (2012) 0.75
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. Neth Heart J (2016) 0.75
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications. Interv Cardiol Clin (2017) 0.75
Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes. Patient Relat Outcome Meas (2010) 0.75
CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med (2017) 0.75
Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS (2016) 0.75
Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention. Front Pharmacol (2016) 0.75
Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics. Pharmaceuticals (Basel) (2010) 0.75
Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study. Br J Clin Pharmacol (2016) 0.75
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med (2010) 9.19
Estimated radiation dose associated with cardiac CT angiography. JAMA (2009) 8.31
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention (2015) 4.00
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 3.84
Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA (2006) 3.78
Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med (2005) 3.75
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation (2010) 3.68
Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA (2005) 3.67
Radiation dose estimates from cardiac multislice computed tomography in daily practice: impact of different scanning protocols on effective dose estimates. Circulation (2006) 3.26
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol (2009) 3.15
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation (2004) 3.12
A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol (2008) 3.11
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med (2004) 3.07
Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet (2006) 2.75
Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease. JACC Cardiovasc Imaging (2009) 2.70
A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol (2004) 2.67
Association of ST-elevation and non-ST-elevation presentation on ECG with transmurality and size of myocardial infarction as assessed by contrast-enhanced magnetic resonance imaging. J Electrocardiol (2013) 2.64
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation (2005) 2.61
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol (2003) 2.53
A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol (2008) 2.49
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J (2009) 2.47
Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost (2008) 2.46
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol (2008) 2.38
Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation (2012) 2.32
Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation (2006) 2.18
Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet (2011) 2.10
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). Eur Heart J (2008) 2.10
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost (2009) 2.09
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (2008) 2.09
Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. J Am Coll Cardiol (2006) 2.08
Image quality and radiation exposure with a low tube voltage protocol for coronary CT angiography results of the PROTECTION II Trial. JACC Cardiovasc Imaging (2010) 2.06
Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J (2009) 2.06
Image quality and radiation exposure with prospectively ECG-triggered axial scanning for coronary CT angiography: the multicenter, multivendor, randomized PROTECTION-III study. JACC Cardiovasc Imaging (2012) 2.05